Amicus Therapeutics News
Most Popular Amicus Therapeutics Story
Shire, Amicus forge $440M pact
Amicus Therapeutics has scored a $50 million upfront payment from Shire's human genetics sub for rights outside the U.S. to three experimental therapies for genetic disorders: Amigal (migalastat Read more...
Latest Headlines
- February 16, 2011
- November 1, 2010
- October 29, 2010
- October 30, 2009
- October 5, 2009
- November 8, 2007
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
